{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:59Z","timestamp":1789726259266,"version":"4.0.1"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first\u2010in\u2010class CD123\u2010targeted therapy, is the only drug approved to treat BPDCN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors conducted a post hoc analysis of the pivotal phase 2 trial to evaluate hematopoietic and BM effects of first\u2010line tagraxofusp treatment (12 \u00b5g\/kg per day on days 1\u20135 of a 21\u2010day cycle) over time.<\/jats:p>\n                    <jats:p>\n                      This trial was registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/\">www.clinicaltrials.gov<\/jats:ext-link>\n                      (ClinicalTrials.gov identifier NCT02113982).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 66 treatment\u2010naive patients in this analysis, 32 had baseline BM disease, and 34 had no BM disease. Over the course of tagraxofusp monotherapy treatment, neutrophil levels restored to normal, mirrored by a decreasing incidence of neutropenia and granulocyte\u2010colony\u2013stimulating factor administration from baseline with each cycle of treatment. Similarly, platelet counts recovered during treatment, whereas thrombocytopenia incidence and requirement for platelet transfusions decreased from baseline. Hemoglobin levels improved during tagraxofusp treatment, correlating with a decrease in the incidence of anemia and the number of transfusions from baseline. By cycle 2, all patients had peripheral blast clearance regardless of BM status. Patients with BM disease who did or did not achieve a complete response\/clinical complete response during treatment experienced similar restoration of hematopoiesis, including peripheral blast eradication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate the on\u2010target effect and unique BM\u2010sparing profile of tagraxofusp, which are paramount when treating myelosuppressive, CD123\u2010positive hematologic diseases. The results support single\u2010agent tagraxofusp as standard\u2010of\u2010care, nonmyelosuppressive first\u2010line treatment for BPDCN and as a potential combination partner for other CD123\u2010positive hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.70243","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:15:22Z","timestamp":1767590122000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hematopoietic effects of tagraxofusp in treatment\u2010naive patients with blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1002","volume":"132","author":[{"given":"Marina","family":"Konopleva","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine\/Montefiore Cancer Center  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra L.","family":"Sweet","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"City of Hope  Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Novant Health Cancer Institute  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"Columbia University Herbert Irving Comprehensive Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zuurman","sequence":"additional","affiliation":[{"name":"Menarini Group  Machelen Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"Menarini Group  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719874733"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.10.3210"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478\u2010200207000\u201000003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701799035"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401743"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102014\u201004\u2010566737"},{"key":"e_1_2_10_8_1","article-title":"Elzonris (tagraxofusp\u2010erzs) injection","author":"US Food and Drug Administration (FDA)","year":"2023","journal-title":"FDA"},{"key":"e_1_2_10_9_1","article-title":"Elzonris [summary of product characteristics]","author":"European Medicines Agency","year":"2021","journal-title":"European Medicines Agency"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000173"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1815105"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00034"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201001968\u2010z"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23567"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4146"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.072645"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201009\u2010529537"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201012\u2010474056"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201029669\u20108"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.6502"},{"key":"e_1_2_10_22_1","article-title":"Efficacy and safety of pivekimab sunirine in patients with blastic plasmacytoid dendritic cell neoplasm in the CADENZA study [abstract]","author":"Pemmaraju N","year":"2025","journal-title":"EHA Library"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00674\u20105"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201016\u20101904"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010008\u20100488\u20106"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1206"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709042501"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrleng.2014.12.006"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010022\u201004356\u20109"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959\u2010019\u20100054\u20105"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.713694"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.13.11967"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_2_10_34_1","article-title":"A study of tagraxofusp in combination with venetoclax and azacitidine in adults with untreated CD123+ acute myeloid leukemia who cannot undergo intensive chemotherapy (TRILLIUM)","author":"Stemline Therapeutics, Inc","year":"2025","journal-title":"Stemline Therapeutics, Inc."},{"key":"e_1_2_10_35_1","article-title":"Phase I\/II study of tagraxofusp in combination with decitabine for patients with myelomonocytic\/myeloproliferative neoplasm and high risk myelodysplastic syndromes","author":"The University of Texas MD Anderson Cancer Center","year":"2025","journal-title":"The University of Texas MD Anderson Cancer Center"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010207503"}],"updated-by":[{"DOI":"10.1002\/cncr.70288","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000}}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:22:37Z","timestamp":1786796557000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1002\/cncr.70243"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70243","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2025-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70243"}}